Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

AFL · Q3 2025 Earnings

Aflac

Reported November 4, 2025

30-second summary

30-second take: Aflac printed $2.49 adjusted EPS on $4.74B revenue (YoY optics distorted by a $1.3B swing from prior-year investment losses to current-quarter gains; net earned premiums were $3.37B, +1.3% YoY) with adjusted ROE of 19.1% (22.1% ex-FX remeasurement), and management materially upgraded the Japan narrative from "stabilization candidate" last quarter to "growth inflection" this quarter — backed by Japan cancer insurance sales +42% YoY (driven largely by Morito) and Sumitas drawing over 50% of buyers from the 30s-40s age cohort vs. a 40% management expectation. The company tightened Japan expense ratio guidance to the lower end of the 20-23% range, disclosed granular new segment margin targets, and bought back a record $1B in Q3. Tone shift from cautious-constructive in Q2 to genuinely bullish, with quantified evidence rather than promises.

Headline numbers

EPS

Q3 FY2025

$2.49

Revenue

Q3 FY2025

$4.74B

+60.7% YoY

Key financials

Q3 FY2025

Metric	Q3 FY2025	YoY	Q2 FY2025	QoQ
Revenue	$4.74B	+60.7%	$4.16B	+13.9%
EPS	$2.49	—	$1.78	+39.9%

Guidance

Aflac provides granular FY2025 guidance for segment benefit, expense, and profit margins; Japan expense ratio tightened to 'lower end' of prior range.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Aflac Japan benefit ratio	FY 2025	58% to 60%	—
Aflac Japan pre-tax profit margin	FY 2025	35% to 38%	—
Aflac U.S. benefit ratio	FY 2025	lower end of 48% to 52%	—
Aflac U.S. expense ratio	FY 2025	mid to upper end of 36% to 39%	—
Aflac U.S. pre-tax profit margin	FY 2025	upper end of 17% to 20%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Aflac Japan expense ratio	FY 2025	20% to 23%	lower end of 20% to 23%	narrowed to lower end of prior range	Lowered

Segment performance

Q3 FY2025

Segment	Q3 FY2025	YoY
Aflac Japan	$1.216B	+13.3%
Aflac U.S.	$0.375B	+7.1%

Capital & returns

Q3 FY2025

Segment	Q3 FY2025
Adjusted Return on Equity (Reported)	19.1%
Adjusted Return on Equity (Excluding FX Remeasurement)	22.1%
Adjusted Book Value Per Share	$53.33
Total Adjusted Debt to Adjusted Capitalization	25.1%

Other KPIs

Q3 FY2025

Segment	Q3 FY2025
Aflac U.S. Premium Persistency (12-month rolling)	79.0%
Aflac U.S. Combined Ratio	78.3%
Aflac U.S. New Annualized Premium Sales	$390 million
Adjusted Earnings Per Share (Diluted)	$2.49

Management tone

Stabilization candidate → Inflection candidate → Quantified inflection → Capacity expansion. The shift across three quarters is dramatic: Q2 was Yoshizumi asserting 2025 sales would exceed 2024; this quarter Dan is volunteering upside surprises with specific numbers attached.

Japan moves from "we think we'll stabilize" to "the model is wrong on the upside." Last quarter management defended a -1.1% premium print as evidence of inflection. This quarter Dan was explicit on Sumitas: "We thought we might do as high as 40% of the people would be what I would call in the 30s and 40s in terms of age. It's actually run over 50%. So, you know, 40 is to 50, 25% better." And on Morito: "The idea of the percentage increase we've had is spectacular this year." These are unqualified statements with quantified surprise upside — a substantive lift from the measured framing of Q2.

US supplemental shifts from "steady state" to "multi-year recovery with proof points." A quarter ago, US growth was being deliberately constrained on quality grounds and 4Q enrollment was the test. This quarter management delivered specific evidence the bundling thesis works: Virgil noted "Every time we sold a dollar of dental, 85 cents worth of VB was sold. That is exactly what we're looking for." Max also confirmed "one of the businesses that's running have turned to profitability this year." Dental is framed as "two years behind" with a 2026 recovery path — this is no longer a steady-state narrative, it's a recovery story with milestones.

Capital deployment urgency returns — selectively. Q2 framing emphasized patience given a flat yield curve. This quarter the company executed a record $1B Q3 buyback. The patience signal hasn't reversed (M&A still framed as low priority: "we are in a position where we don't have to do anything"), but the buyback pace tells you management thinks the stock-vs-cash trade has tilted.

Forecasting confidence is up. The granular new segment margin disclosures (Japan and US pre-tax profit margins, both benefit and expense ratios) replace the qualitative "solid second half" framing of Q2. Management is now willing to commit to specific bands across five segment-level metrics — a meaningful confidence signal.

Recurring themes management leaned on this quarter:

Japan sales acceleration driven by cancer (Morito +42% YoY) and younger demographic penetration via repriced SumitasaUS supplemental recovery narrative: dental stabilized (+40% 9M growth), LAD turning profitable, bundling thesis working (85 cents VB per dollar dental)Actuarial assumption unlocks creating near-term earnings tailwind but management guiding conservatively on future improvementsCapital deployment confidence: record $1B buyback Q3, 43 consecutive years dividend increases, maintaining 19%+ ROEOrganizational restructuring enabling concurrent multi-product launches in Japan; US moving to tiered underwriting by profitabilityFX and reinsurance-driven FSA earnings sustainability questioned; core underlying Japan FSA ~200B yen annually

Risks management surfaced:

Yen strengthening could reverse FX tailwinds from maturing USD-denominated assets in JapanCannibalization risk of cancer (Morito) sales when medical insurance launches end-December; management acknowledges 'there always is some decline in sales of an older product'US producer base remains weak; average producer productivity insufficient to drive individual sales growth without headcount recoveryPrivate credit liquidity risk if systemic credit cycle turns; though management notes portfolio performs well with isolated exposure to troubled namesUS benefit ratio structural drift upward as mix shifts to higher-ratio products (LAD, dental); management attributing to endorsement/enhancement decisions and pandemic catching-up claims

Answers to last quarter's watch list

Japan sales trajectory vs. Yoshizumi's commitment — Validated emphatically. Japan cancer insurance sales +42% YoY (driven largely by Morito); Sumitas attracting >50% of buyers from the 30s-40s cohort vs. 40% expectation. The "2025 > 2024" assertion now looks conservative.

Resolved positively

Japan premium trend — Japan pretax adjusted earnings grew +13.3% YoY in Q3 (in dollars; +13.1% in yen), though net earned premiums declined 4% YoY (underlying ex-DPL/paid-up/reinsurance only -1.2%). Management is publicly modeling Japan pre-tax margin at 35-38% with benefit ratio at 58-60% — signals of confidence that the underlying business is stabilizing. The narrower 58-60% range (vs. standard 58-62%) is the cleanest tell.

Resolved positively

US 4Q enrollment — Inconclusive on this print; Q4 is the actual enrollment quarter. US new annualized premium sales of $390M (+2.8% YoY) edged Q2's +2.7% pace, but the decisive read is next quarter. Management's "scaling new business lines" framing in the US expense ratio guide signals continued investment.

Continue monitoring

Holding company cash deployment — Decisively resolved: record $1B buyback in Q3. Management's stance has shifted from "patience given flat curve" to active deployment, though M&A remains explicitly deprioritized.

Resolved positively

Lapse activity tied to Miraito refresh — US 12-month rolling premium persistency printed 79.0%. Management acknowledged that "there always is some decline in sales of an older product" as cannibalization from the new December medical launch is anticipated, but persistency wasn't flagged as deteriorating.

Continue monitoring

USP regulatory model approval — The company didn't call this out on the print.

Continue monitoring

What to watch into next quarter

December medical insurance launch traction in Japan — three-brand parallel strategy is unprecedented for Aflac Japan. Watch first-quarter sales contribution and whether Morito cannibalization stays modest (management flagged "some decline" as expected).

US combined ratio trend — drifted +80bps QoQ to 78.3% on product mix. Watch whether the FY2025 US benefit ratio actually lands at "lower end of 48-52%" or whether mix shift pushes it higher.

Q4 US new annualized premium sales growth — Q4 is the seasonally critical enrollment quarter. The Q2 thesis was "stronger 2H driven by 4Q." Watch whether US sales growth steps decisively above the Q3 +2.8% pace.

Buyback pace post-record-quarter — $1B in Q3 sets a high bar. A material step-down would signal management views the stock as fairly valued at current levels; a continued elevated pace would reinforce the conviction signal.

Japan FSA earnings sustainability — management flagged core underlying Japan FSA at ~200B yen annually with FX/reinsurance distorting the headline. Watch for cleaner disclosure of the underlying run rate.

Private credit portfolio commentary — management characterized exposure as "nothing systemic" but acknowledged some isolated names; any escalation would matter given the 19%+ ROE relies partly on investment income discipline.

Sources

Aflac Q3 2025 Financial Supplement, filed with SEC: https://www.sec.gov/Archives/edgar/data/4977/000162828025048906/afl093025-fabdocument.htm
Aflac Q3 2025 earnings call commentary (Dan Amos, Max Brodén, Virgil Miller, Masatoshi Koide, Yoshizumi).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.